Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R9QW
|
||||
| Former ID |
DIB004824
|
||||
| Drug Name |
Activin-like kinase 5 inhibitor
|
||||
| Synonyms |
Activin-like kinase 5 inhibitor (scar formation); ALK-5 inhibitor (scar formation), Graceway Pharmaceuticals; ALK-5 inhibitor (scar formation), Pfizer; Activin-like kinase-5 inhibitor (scar formation), Graceway Pharmaceuticals; Activin-like kinase-5 inhibitor (scar formation), Pfizer
|
||||
| Indication | Scar tissue [ICD10:L00-L99] | Investigative | [1] | ||
| Company |
Pfizer Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
n1ccc2sc(cc2c1)c1c(cnn1c1nc(ccc1)C)C
|
||||
| Target and Pathway | |||||
| Target(s) | TGF-beta receptor type I | Target Info | Inhibitor | [2] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Cytokine-cytokine receptor interaction | |||||
| FoxO signaling pathway | |||||
| Endocytosis | |||||
| TGF-beta signaling pathway | |||||
| Osteoclast differentiation | |||||
| Hippo signaling pathway | |||||
| Adherens junction | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Hepatitis B | |||||
| HTLV-I infection | |||||
| Pathways in cancer | |||||
| Colorectal cancer | |||||
| Pancreatic cancer | |||||
| Chronic myeloid leukemia | |||||
| PANTHER Pathway | TGF-beta signaling pathway | ||||
| Pathway Interaction Database | Glypican 1 network | ||||
| ALK1 signaling events | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| TGF-beta receptor signaling | |||||
| Reactome | TGF-beta receptor signaling activates SMADs | ||||
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | |||||
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | |||||
| SMAD2/3 MH2 Domain Mutants in Cancer | |||||
| TGFBR2 Kinase Domain Mutants in Cancer | |||||
| TGFBR1 KD Mutants in Cancer | |||||
| TGFBR1 LBD Mutants in Cancer | |||||
| WikiPathways | TGF Beta Signaling Pathway | ||||
| p38 MAPK Signaling Pathway | |||||
| MAPK Signaling Pathway | |||||
| TGF beta Signaling Pathway | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| Cardiac Hypertrophic Response | |||||
| Signaling by TGF-beta Receptor Complex | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| References | |||||
| REF 1 | An activin receptor-like kinase 5 inhibitor reduces collagen deposition in a rat dermal incision wound healing model. Plast Reconstr Surg. 2011 Nov;128(5):451e-459e | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.